Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Dow Jones Industrial Average ETF Trust (Symbol: DIA) where we have detected an approximate $1.1 billion dollar inflow -- that's a 2.6% increase week over week in outstanding units (from 88,742,867 to 91,042,867). Among the largest underlying components of DIA, in trading today Goldman Sachs Group Inc (Symbol: GS) is up about 0.5%, Microsoft Corporation (Symbol: MSFT) is off about 1.1%, and Amgen Inc (Symbol: AMGN) is higher by about 0.7%. For a complete list of holdings, visit the DIA Holdings page » The chart below shows the one year price performance of DIA, versus its 200 day moving average:
Looking at the chart above, DIA's low point in its 52 week range is $366.32 per share, with $505.30 as the 52 week high point — that compares with a last trade of $492.88. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Insurance Brokers Dividend Stocks
FTK Stock Predictions
MNSO Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable ETF Inflow Detected - DIA, GS, MSFT, AMGN

Looking at the universe of stocks we cover at Dividend Channel, on 2/13/26, Cencora Inc (Symbol: COR), Amgen Inc (Symbol: AMGN), and Oppenheimer Holdings Inc Class A (D (Symbol: OPY) will all trade ex-dividend for their respective upcoming dividends. Cencora Inc will pay its quarterly dividend of $0.60 on 3/2/26, Amgen Inc will pay its quarterly dividend of $2.52 on 3/6/26, and Oppenheimer Holdings Inc Class A (D will pay its quarterly dividend of $0.18 on 2/27/26. As a percentage of COR's recent stock price of $360.00, this dividend works out to approximately 0.17%, so look for shares of Cencora Inc to trade 0.17% lower — all else being equal — when COR shares open for trading on 2/13/26. Similarly, investors should look for AMGN to open 0.69% lower in price and for OPY to open 0.20% lower, all else being equal.
When an S&P 1500 component reaches 20 years of dividend increases, it becomes a contender to join the elite "Dividend Aristocrats" index. Amgen Inc (Symbol: AMGN) is a "future dividend aristocrats contender," with 14+ years of increases.
Below are dividend history charts for COR, AMGN, and OPY, showing historical dividends prior to the most recent ones declared.
Cencora Inc (Symbol: COR):
Amgen Inc (Symbol: AMGN):
Oppenheimer Holdings Inc Class A (D (Symbol: OPY):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 0.67% for Cencora Inc, 2.76% for Amgen Inc, and 0.80% for Oppenheimer Holdings Inc Class A (D.
In Wednesday trading, Cencora Inc shares are currently off about 0.9%, Amgen Inc shares are down about 3%, and Oppenheimer Holdings Inc Class A (D shares are down about 2.8% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
Also see:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ex-Dividend Reminder: Cencora, Amgen and Oppenheimer Holdings

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Dow Jones Industrial Average ETF Trust (Symbol: DIA) where we have detected an approximate $268.9 million dollar outflow -- that's a 0.6% decrease week over week (from 89,042,867 to 88,492,867). Among the largest underlying components of DIA, in trading today Sherwin-Williams Co (Symbol: SHW) is up about 1.1%, Amgen Inc (Symbol: AMGN) is up about 2%, and Travelers Companies Inc (Symbol: TRV) is up by about 0.8%. For a complete list of holdings, visit the DIA Holdings page » The chart below shows the one year price performance of DIA, versus its 200 day moving average:
Looking at the chart above, DIA's low point in its 52 week range is $366.32 per share, with $497.76 as the 52 week high point — that compares with a last trade of $497.01. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
EBAY DMA
CHSCL Historical Stock Prices
Institutional Holders of CTCX
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

DIA, SHW, AMGN, TRV: ETF Outflow Alert

Key Points
Weight loss candidates from Amgen and Roche performed well in phase 2 studies.
These could be exciting additions to these companies' drug portfolios.
Both drugmakers have attractive lineups and deep pipelines beyond this area.
During the first half of 2025, Wegovy and Zepbound, two weight loss drugs, ranked among the top 10 best-selling medicines worldwide. And given current projections for this market, we could see more weight management therapies among the top-selling drugs in the next five years.
Two companies inching closer to launching anti-obesity medicines are Amgen (NASDAQ: AMGN) and Roche (OTC: RHHB.Y). Should investors consider purchasing shares of these leading drugmakers?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
1. Amgen
Amgen's leading weight loss candidate is called MariTide. Last year, it completed phase 2 studies. In the 52-week trial, the medicine led to an average weight loss of up to 20%. One important differentiator MariTide may have is that it could be administered monthly. The current market leaders, Wegovy and Zepbound, are taken weekly. Even with lower efficacy, MariTide could attract enough patients with a friendlier dosing regimen.
Amgen started phase 3 studies for MariTide late last year across diabetes and weight management. If all goes well, the medicine could earn approval within three years. It would be a great addition to Amgen's lineup. Although the biotech company performed well last year, it lost patent exclusivity for denosumab, an important growth driver indicated for the treatment of certain bone conditions, in 2025.
Thankfully, over the next few years, Amgen should earn approval for several newer products. The company's bemarituzumab, an investigational therapy for gastric cancer, performed well in phase 3 studies last year, as did rocatinlimab, a medicine for eczema.
Amgen still has several drugs that will help pull its sales in the right direction. These include Tezspire, a medicine for asthma, and Repatha, used to lower bad cholesterol, among others. Lastly, Amgen is a great dividend stock, having increased its payouts every year since initiating them in 2011. The stock's foray into weight management could help, but there are many other reasons to invest in Amgen.
2. Roche
Roche recently made headlines thanks to the strong performance of its anti-obesity candidate, CT-388, in phase 2 studies. The medicine led to a placebo-adjusted 22.5% weight loss at the highest dose in the 48-week trial. Roche is now planning to start a pair of phase 3 studies for CT-388 in obesity this quarter. Roche has a couple of other weight management candidates in the pipeline, including CT-996, which could be an oral option.
Within a few years, it could launch at least one of them, probably CT-388, since it is currently the most advanced. This medicine would add to a list of several growth drivers that Roche already has, including cancer drug Tecentriq and Vabysmo, which treats several eye-related diseases. These and other products will contribute to Roche's top-line until 2038, according to management.
And beyond weight loss candidates, Roche has a deep pipeline that will help it expand its lineup. Roche is performing well for a reason: The stock looks like a strong buy-and-hold option.
Should you buy stock in Amgen right now?
Before you buy stock in Amgen, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $432,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,067,820!*
Now, it’s worth noting Stock Advisor’s total average return is 894% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 5, 2026.
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends Roche Holding AG. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys?

For Immediate Release
Chicago, IL – February 5, 2026 – Today, Zacks Investment Ideas feature highlights Amgen AMGN, Apple AAPL and Microsoft MSFT.
Amgen Stock Hits 52-Week High: A Buy Signal?
Amgen is having a moment. The biotech bellwether is trading near fresh 52-week highs, up roughly 8% in the latest session, and the tape is sending a clear message: institutions are leaning in. When a mega-cap healthcare name breaks out while the broader market debates growth versus defensives, investors should pay attention. The numbers tell a compelling story.
At yesterday afternoon's earnings report, Amgen reported solid growth in the fourth quarter and full year 2025, with total revenues rising roughly 9% in Q4 to about $9.9 billion and 10% for the full year to approximately $36.8 billion, driven by volume gains across its diversified product portfolio.
Zooming out, AMGN has quietly put together a strong run: up about 13.7% over the last three months and roughly 11% year-to-date. This is steady accumulation in a $193 billion leader with a deep commercial portfolio and a pipeline that's starting to get more credit. The key question is whether this move is just a "safe haven" bid, or the start of a higher valuation regime driven by earnings power and catalysts.
Amgen Stock Breakout: Why It Matters
A 52-week high is more than a headline, it's a signal. New highs tend to attract momentum capital, force underweight managers to chase, and create a self-reinforcing setup as technical buyers step in. For AMGN stock, the breakout is also happening with fundamental backing: revenue growth is running at 10%, which is a notable pace for a mature biopharma franchise.
AMGN's durability comes from a broad portfolio of cash-generating therapies across inflammation, oncology, bone health, and rare disease. Products like Enbrel, Otezla, Prolia/XGEVA, Repatha, and KYPROLIS anchor the base, while newer and partnered assets add incremental growth vectors. That breadth matters in 2026's market, where single-product stories routinely get rerated on one trial readout.
Just as important, the breakout is happening without "story stock" valuation excess. AMGN trades around 25.2x trailing earnings, but the forward P/E of 15.6x is the number that jumps off the screen. That multiple is not pricing in blue-sky outcomes. And when a stock pushes to highs on a reasonable forward multiple, it often indicates the market is starting to believe the forward earnings path is sturdier than previously assumed.
AMGN Share Valuation: Earnings Power Looks Underpriced
Looking at the fundamentals, AMGN's earnings profile remains the backbone of the bull case. Current-year EPS is about $22.33, with next-year EPS expected near $22.92. That's not a "hypergrowth" curve, but in large-cap pharma, consistency is the feature. A stock doesn't need explosive EPS growth to outperform if the market is underestimating durability, margin resilience, or the contribution from new launches.
Consensus expects continued execution from Amgen's diversified lineup, and the valuation suggests skepticism remains. Put differently: the market is paying a mid-teens forward multiple for a company delivering double-digit revenue growth. That mismatch is exactly what tends to show up in breakout charts.
Wall Street's price target tape also reflects improving sentiment. Recent target moves include RBC lifting its target to $360 (Outperform) and Goldman Sachs reiterating a Buy while raising its target to $415. Cantor Fitzgerald moved its target to $350 while staying Neutral—an important detail because even the more cautious firms have been forced to lift numbers as the stock grinds higher. Whisper numbers suggest the next leg higher comes from evidence that newer assets and the pipeline are translating into durable, multi-year revenue streams.
Amgen Catalysts and What's Next for the Stock
For investors chasing a 52-week high, the right move is not to stare at the chart, but to define the catalysts that keep the bid under the stock.
Key catalysts ahead include continued portfolio expansion and pipeline progress. Amgen has been active in building a broader growth engine beyond legacy blockbusters, and the market tends to reward large biopharma when it proves it can refresh the franchise without sacrificing profitability. The pipeline is the optionality, but commercial execution is the cash register.
The segment/metric that is the number to watch is forward EPS progression versus the current valuation. If AMGN can keep next-year EPS expectations firm (or nudging higher) while maintaining its double-digit revenue growth trajectory, the market has room to re-rate the multiple. That's how a "defensive" becomes a "defensive growth" compounder—and those are scarce.
Another underappreciated catalyst: relative attractiveness versus mega-cap tech stocks. Apple trades around 32.1x earnings, and Microsoft trades near 24.3x. Both are elite businesses, but their valuations already reflect premium expectations. By contrast, AMGN stock at a 15.6x forward P/E offers a different risk/reward profile, less dependent on multiple expansion and more tied to execution and cash generation. In a market where rates and risk appetite can change quickly, that valuation gap matters.
What AMGN Stock's New High Says
AMGN stock hitting 52-week highs is a bullish tell, and it's supported by fundamentals, not hype. A near-$360 price with strong recent momentum, ~10% revenue growth, and a forward P/E around 15.6x creates a setup where investors get quality, scale, and catalysts without paying a tech-style premium. The numbers tell a compelling story.
The clean takeaway for investors: treat the breakout as confirmation that Amgen may be back in leadership mode. With reasonable valuation, improving sentiment, and multiple fundamental levers, AMGN looks positioned to remain a core large-cap healthcare winner, even as Apple and Microsoft and other big tech/AI names continue to dominate the conversation.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Zacks Investment Ideas feature highlights: Amgen, Apple and Microsoft

U.S. stock markets closed mixed on Wednesday as sector rotation by market participants continued. Investors remained concerned about the significantly overstretched valuation of technology stocks, especially artificial intelligence (AI)-centric stocks. Growth-oriented S&P 500 and Nasdaq Composite ended in negative territory, while the value-oriented Dow finished in positive territory.
How Did the Benchmarks Perform?
The Dow Jones Industrial Average (DJI) rose 0.5% or 260.31 points to close at 49,501.30. Notably, 23 components of the 30-stock index ended in positive territory and seven in negative territory. The tech-heavy Nasdaq Composite finished at 22,904.58, sliding 1.5% or 350.61 points on the weak performance of AI-powered semiconductor bigwigs.
The S&P 500 fell 0.5% to finish at 6,882.72. Six out of the11 broad-sectors of the broad-market index ended in negative territory while five ended in positive territory. The Technology Select Sector SPDR (XLK), the Communication Select Sector SPDR (XLC) and the Health Care Select Sector SPDR (XLV) tumbled 2.2%, 1.6% and 1%, respectively.
On the other hand, the Energy Select Sector SPDR (XLE), the Materials Select Sector SPDR (XLB), the Consumer Staples Select Sector SPDR (XLP) and the Utilities Select Sector SPDR (XLU) advanced 3.2%, 2.1%, 1.6% and 1.5%, respectively.
The fear gauge, the CBOE Volatility Index (VIX) was up 3.6% to 18.64. A total of 24.60 billion shares were traded on Wednesday, higher than the last 20-session average of 19.90 billion. The S&P 500 recorded 93 new 52-week highs and 23 new 52-week lows. The Nasdaq Composite registered 218 new 52-week highs and 318 new 52-week lows.
Sector Churn Continues
Advanced Micro Devices Inc. AMD reported fourth-quarter 2025 non-GAAP earnings of $1.53 per share, which beat the Zacks Consensus Estimate of $1.32 per share. The figure jumped 40.4% year over year and 27.5% sequentially. Revenues of $10.27 billion beat the Zacks Consensus Estimate by 6.24%. The topline increased 34.1% year over year and 11.1% sequentially.
Management expects first-quarter 2026 revenues of $9.8 billion (+/-$300 million). At the mid-point of the revenue range, this represents year-over-year growth of approximately 32% and a sequential decline of approximately 5%.
However, investors’ expectations were sky-high buoyed by the company’s innovative AI chip portfolio. As a result, the stock price plummeted 17.3%. Advanced Micro Devices currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Amgen Inc. AMGN reported fourth-quarter 2025 adjusted earnings of $5.29 per share, which beat the Zacks Consensus Estimate of $4.76 per share. Earnings were relatively flat year over year as higher revenues were partially offset by higher operating costs. Total revenues of $9.9 billion beat the Zacks Consensus Estimate of $9.5 billion. Total revenues rose 9% year over year. The stock price jumped 8.2% after the result. Amgen currently carries a Zacks Rank #3 (Hold).
Economic Data
Payrolls processing firm Automatic Data Processing Inc. ADP reported that private payrolls increased by 22,000 in January, following a downwardly revised 35,000 jobs in December. The consensus estimate was 45,000. Wage rate for those staying in their existing jobs increased 4.5% year-over-year in January.
Institute of Supply Management (ISM) reported that service sector PMI (purchasing managers’ index) came in at 53.8%, marginally below the consensus estimate of 54%. December’s metric was revised downward to 53.8% from 54.4% reported earlier. Any reading above 50% indicates an expansion in service activities.
The U.S. Energy Information Administration (EIA) reported that for the week ended Jan. 30, U.S. commercial crude oil inventories (excluding those in the Strategic Petroleum Reserve) decreased by 3.5 million barrels from the previous week.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stock Market News for Feb 5, 2026

Wednesday, February 4th, 2026
Stock market rotation out of software and tech in general was on clear display today, with the tech-heavy Nasdaq and Nasdaq-exposed S&P 500 hitting the closing bell lower by -1.51% and -0.51%, respectively. The small-cap Russell 2000 fell -0.67% on the day. The Dow is up +0.9% over the past five trading days; the other three indexes are negative over that time.
That the Dow would gain when tech-heavy indexes would be shedding growth is a very direct link to the rotation trade — leaving highly valued, potentially overextended AI buildouts for Mom & Pop portfolio stocks. Strong earnings from Amgen AMGN this morning led that stock up +8% today, leading the Dow 30 index. 3M MMM was up +5%.
Services PMI in Growth Territory: S&P, ISM
Shortly after the market opened this morning, the final S&P Services PMI report came out for January. It posted a slightly better-than-expected +52.7. ISM Services, also for January, went to +53.8%, ahead of expectations and matching its previous-month growth rate. Both metrics are solidly above the 50 levels, as today’s services-heavy private-sector ADP ADP report would attest.
Earnings Roundup After the Closing Bell
Alphabet GOOGL easily surpassed estimates on both top and bottom lines for its Q4 report this afternoon. Earnings of $2.82 per share was well ahead of the $2.58 projected, which itself represented +16% sales growth over the past year. Revenues beat estimates by more than $2.5 billion to $97.23 billion (minus Traffic Acquisition Costs [TAC], which the company does not subtract from its top line. GOOGL reported $113.8 billion in its Q4 report).
Clouds growth was better than expected, $17.7 billion versus $16.2 billion, and +48% year over year. YouTube was a smidge light at $11.3 billion, and Waymo self-driving auto service led its Other Bets category with $126 billion in revenues. Biggest of all, Google Search Ad Revenue grew to $63.07 billion from $61.47 billion anticipated.
Alphabet is one corporation already putting its AI functions to work, most visibly with its Search assistant Gemini, but the new Capital Expenditures target is up by more than $50 BILLION from where it had been expected, to a new range of $175-185 billion. This feeds into the “over-invested in AI” caution we’ve seen elsewhere this earnings season, and shares are trading somewhat lower in the after-market.
Qualcomm QCOM reported mixed fiscal Q1 results this afternoon, with earnings of $3.50 per share easily outpacing the $3.39 in the Zacks consensus, and the $3.41 per share reported in the year-ago quarter. Revenues, however, reached $12.25 billion, shy of the $12.28 billion analysts had been expecting. Further, a decline in memory chips is pulling down current-quarter guidance, and QCOM shares are down -9% as a result.
e.l.f. Beauty ELF posted big positive surprises in its fiscal Q3 numbers after the close today, with earnings of $1.24 per share on $490 million in revenues careening past expectations of $0.73 per share on $462.77 million, which itself represented +30% growth year over year. Much of the cosmetics major’s success came from the recent acquisition of Hailey Bieber’s Rhode brand. Shares had initially spiked +16% on the news, but have settled down in the half hour since.
Questions or comments about this article and/or author? Click here>>
Free Report: Profiting from the 2nd Wave of AI Explosion
The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.
Investors who bought shares like Nvidia at the right time have had a shot at huge gains.
But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.
Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.
Access AI Boom 2.0 now, absolutely free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Rotation Trade a Boon for Dow 30 Today

Amgen (AMGN) is having a moment. The biotech bellwether is trading near fresh 52-week highs, up roughly 8% in the latest session, and the tape is sending a clear message: institutions are leaning in. When a mega-cap healthcare name breaks out while the broader market debates growth versus defensives, investors should pay attention. The numbers tell a compelling story.
At yesterday afternoon’s earnings report, Amgen reported solid growth in the fourth quarter and full year 2025, with total revenues rising roughly 9% in Q4 to about $9.9 billion and 10% for the full year to approximately $36.8 billion, driven by volume gains across its diversified product portfolio.
Zooming out, AMGN has quietly put together a strong run: up about 13.7% over the last three months and roughly 11% year-to-date. This is steady accumulation in a $193 billion leader with a deep commercial portfolio and a pipeline that’s starting to get more credit. The key question is whether this move is just a “safe haven” bid, or the start of a higher valuation regime driven by earnings power and catalysts.
Image Source: Zacks Investment Research
Amgen Stock Breakout: Why It Matters
A 52-week high is more than a headline, it’s a signal. New highs tend to attract momentum capital, force underweight managers to chase, and create a self-reinforcing setup as technical buyers step in. For AMGN stock, the breakout is also happening with fundamental backing: revenue growth is running at 10%, which is a notable pace for a mature biopharma franchise.
Image Source: TradingView
AMGN’s durability comes from a broad portfolio of cash-generating therapies across inflammation, oncology, bone health, and rare disease. Products like Enbrel, Otezla, Prolia/XGEVA, Repatha, and KYPROLIS anchor the base, while newer and partnered assets add incremental growth vectors. That breadth matters in 2026’s market, where single-product stories routinely get rerated on one trial readout.
Just as important, the breakout is happening without “story stock” valuation excess. AMGN trades around 25.2x trailing earnings, but the forward P/E of 15.6x is the number that jumps off the screen. That multiple is not pricing in blue-sky outcomes. And when a stock pushes to highs on a reasonable forward multiple, it often indicates the market is starting to believe the forward earnings path is sturdier than previously assumed.
AMGN Share Valuation: Earnings Power Looks Underpriced
Looking at the fundamentals, AMGN’s earnings profile remains the backbone of the bull case. Current-year EPS is about $22.33, with next-year EPS expected near $22.92. That’s not a “hypergrowth” curve, but in large-cap pharma, consistency is the feature. A stock doesn’t need explosive EPS growth to outperform if the market is underestimating durability, margin resilience, or the contribution from new launches.
Consensus expects continued execution from Amgen’s diversified lineup, and the valuation suggests skepticism remains. Put differently: the market is paying a mid-teens forward multiple for a company delivering double-digit revenue growth. That mismatch is exactly what tends to show up in breakout charts.
Wall Street’s price target tape also reflects improving sentiment. Recent target moves include RBC lifting its target to $360 (Outperform) and Goldman Sachs reiterating a Buy while raising its target to $415. Cantor Fitzgerald moved its target to $350 while staying Neutral—an important detail because even the more cautious firms have been forced to lift numbers as the stock grinds higher. Whisper numbers suggest the next leg higher comes from evidence that newer assets and the pipeline are translating into durable, multi-year revenue streams.
Amgen Catalysts and What's Next for the Stock
For investors chasing a 52-week high, the right move is not to stare at the chart, but to define the catalysts that keep the bid under the stock.
Key catalysts ahead include continued portfolio expansion and pipeline progress. Amgen has been active in building a broader growth engine beyond legacy blockbusters, and the market tends to reward large biopharma when it proves it can refresh the franchise without sacrificing profitability. The pipeline is the optionality, but commercial execution is the cash register.
The segment/metric that is the number to watch is forward EPS progression versus the current valuation. If AMGN can keep next-year EPS expectations firm (or nudging higher) while maintaining its double-digit revenue growth trajectory, the market has room to re-rate the multiple. That’s how a “defensive” becomes a “defensive growth” compounder—and those are scarce.
Another underappreciated catalyst: relative attractiveness versus mega-cap tech stocks. Apple (AAPL) trades around 32.1x earnings, and Microsoft (MSFT) trades near 24.3x. Both are elite businesses, but their valuations already reflect premium expectations. By contrast, AMGN stock at a 15.6x forward P/E offers a different risk/reward profile, less dependent on multiple expansion and more tied to execution and cash generation. In a market where rates and risk appetite can change quickly, that valuation gap matters.
Image Source: Zacks Investment Research
What AMGN Stock’s New High Says
AMGN stock hitting 52-week highs is a bullish tell, and it’s supported by fundamentals, not hype. A near-$360 price with strong recent momentum, ~10% revenue growth, and a forward P/E around 15.6x creates a setup where investors get quality, scale, and catalysts without paying a tech-style premium. The numbers tell a compelling story.
The clean takeaway for investors: treat the breakout as confirmation that Amgen may be back in leadership mode. With reasonable valuation, improving sentiment, and multiple fundamental levers, AMGN looks positioned to remain a core large-cap healthcare winner, even as Apple and Microsoft and other big tech/AI names continue to dominate the conversation.
Free Report: Profiting from the 2nd Wave of AI Explosion
The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.
Investors who bought shares like Nvidia at the right time have had a shot at huge gains.
But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.
Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.
Access AI Boom 2.0 now, absolutely free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Apple Inc. (AAPL) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Broadcom Inc (Symbol: AVGO), where a total of 236,919 contracts have traded so far, representing approximately 23.7 million underlying shares. That amounts to about 92.5% of AVGO's average daily trading volume over the past month of 25.6 million shares. Particularly high volume was seen for the $295 strike put option expiring February 04, 2026, with 17,878 contracts trading so far today, representing approximately 1.8 million underlying shares of AVGO. Below is a chart showing AVGO's trailing twelve month trading history, with the $295 strike highlighted in orange:
Alphabet Inc (Symbol: GOOG) saw options trading volume of 184,641 contracts, representing approximately 18.5 million underlying shares or approximately 87.1% of GOOG's average daily trading volume over the past month, of 21.2 million shares. Particularly high volume was seen for the $335 strike put option expiring March 20, 2026, with 10,701 contracts trading so far today, representing approximately 1.1 million underlying shares of GOOG. Below is a chart showing GOOG's trailing twelve month trading history, with the $335 strike highlighted in orange:
And Amgen Inc (Symbol: AMGN) saw options trading volume of 24,308 contracts, representing approximately 2.4 million underlying shares or approximately 85.1% of AMGN's average daily trading volume over the past month, of 2.9 million shares. Particularly high volume was seen for the $295 strike call option expiring February 20, 2026, with 2,402 contracts trading so far today, representing approximately 240,200 underlying shares of AMGN. Below is a chart showing AMGN's trailing twelve month trading history, with the $295 strike highlighted in orange:
For the various different available expirations for AVGO options, GOOG options, or AMGN options, visit StockOptionsChannel.com.
Also see:
Office Supplies Dividend Stocks
TMO Historical PE Ratio
RML Split History
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Wednesday Option Activity: AVGO, GOOG, AMGN

In early trading on Wednesday, shares of GE HealthCare Technologies topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.3%. Year to date, GE HealthCare Technologies registers a 0.2% gain.
And the worst performing Nasdaq 100 component thus far on the day is Applovin, trading down 14.0%. Applovin is lower by about 41.1% looking at the year to date performance.
Two other components making moves today are Advanced Micro Devices, trading down 11.5%, and Amgen, trading up 3.4% on the day.
VIDEO: Nasdaq 100 Movers: APP, GEHC
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.